Key Messages

This narrative review compiles evidence that has been generated during the last 20 years on the use of pimecrolimus 1% cream in infants for the treatment of atopic dermatitis. The authors believe this work is of interest to the readers of Pediatric Immunology & Allergy, since use of pimecrolimus is still restricted to children aged 2 years and above in most countries, including European countries. According to the evidence and the opinion of the authors there is currently no reason to support this restriction any longer. The authors hope this review will convince the readers to initiate treatment of atopic dermatitis already during infancy and to consider topical pimecrolimus as an alternative to topical corticosteroids for the treatment of atopic dermatitis in infants aged 3 months and above.